Kodiak Sciences Inc.
KOD Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$91.32
KIRA · Stoqly’s AI analyst, in plain words
- Kodiak Sciences Inc. lost $230M in fiscal 2025.
- Free cash flow was −$137M in fiscal 2025, — of revenue.
Market cap
$5.7B
P/E
—
Revenue
—
Net income
−$230M
Free cash flow
−$137M
Operating margin
—
Kodiak Sciences Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$230M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Kodiak Sciences Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Kodiak Sciences Inc.
- CIK
- 0001468748
Kodiak Sciences Inc. · KOD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$267M | −$334M | −$260M | −$176M | −$230M |
| Diluted EPS | −$5.16 | −$6.39 | −$4.97 | −$3.35 | −$4.32 |
| Cash | |||||
| Cash from operations | −$182M | −$206M | −$154M | −$117M | −$136M |
| Capital expenditure | $17.0M | $37.0M | $41.4M | $0.4M | $0.5M |
| Free cash flow | −$199M | −$243M | −$196M | −$118M | −$137M |
| Share count change | 13.2% | 0.9% | 0.3% | 0.3% | 1.2% |
| Debt and strength | |||||
| Cash and short-term investments | $732M | $479M | $286M | $168M | $210M |
| Shareholders' equity | $663M | $436M | $266M | $150M | $157M |
| Current ratio | 11.4x | 9.3x | 6.9x | 6.7x | 4.7x |
| Interest coverage | −5,681.9x | −18,965.5x | −21,332.4x | — | — |
| Returns and quality | |||||
| Return on equity | −35.0% | −60.7% | −74.2% | −84.7% | −149.5% |
| Return on tangible equity | −40.3% | −76.5% | −98.0% | −117.2% | −146.1% |
| Altman Z'' | 3.8 | −1.6 | −7.0 | −12.9 | −14.9 |
Insiders bought, 12 months
$217M
4 insiders
Insiders sold, 12 months
$4.9M
1 insider
Of sales under plans
100%
$4.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kodiak Sciences Inc. · KOD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $91.32 a share, the company is worth $5.7B.
Source: SEC EDGAR XBRL filings (CIK 0001468748). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.